CTSH vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 11, 2026
CTSH
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | CTSH | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 9.6061 | 23.0415 | CTSH |
| PEG Ratio | 0.873 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 4.5% | 2.1% | CTSH |
| Earnings Growth | 3.8% | -85.1% | CTSH |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 29.7/100 | 39.1/100 | MRNA |
| Profit Margin | 10.3% | -141.4% | CTSH |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | SELL | SELL | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
CTSH
MarkupPrice above SMA50, rising 50-day trend (12.0% over 20 days), RSI 52
MRNA
MarkupPrice above SMA50, rising 50-day trend (50.4% over 20 days), RSI 61
Fundamentals Snapshot
| Metric | CTSH | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 9.5 | -29.2 |
| Trailing P/E | 12.5 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 0.0% |
| Gross Margin | 0.3% | -0.7% |
| Operating Margin | 0.2% | -5.6% |
| EPS | 4.66 | -8.03 |
| Dividend Yield | 0.02% | — |